REG - Clean Power Hydrogen - Significant Milestones Delivered

Clean Power HydrogenAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR0153Ma&default-theme=true

RNS Number : 0153M  Clean Power Hydrogen PLC  18 December 2025

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No.
596/2014 which is part of UK law by virtue of the European
Union (withdrawal) Act 2018. Upon the publication of this announcement, this
inside information is now considered to be in the public domain.

18 December 2025

Clean Power Hydrogen plc

("CPH2", the "Company" or the "Group)

Significant Milestones Delivered

CPH2, developer of the market disrupting and IP protected Membrane-Free
Electrolyser ("MFE"), announces the successful completion of the Level 1
Factory Acceptance Test ("FAT") of its MFE220 1MW unit, with proven high
purity hydrogen and oxygen output levels facilitating access to new markets
including semiconductors, data centres and pharmaceuticals.

Highlights

·      Major milestone delivered with the Company's next generation
MFE220 1MW successfully completing its internal Level 1 Factory Acceptance
Test. The intended customer, Lagan MEICA, formally witnessed and validated the
process for internal testing.

·      Building on this success the board has instructed the R&D and
Engineering teams to commence the Front-End Engineering Design ("FEED") of a
5MW unit using the same proven and patented technology. The initial
engineering assessment is that both the 5MW and existing 1MW unit can achieve
class leading efficiency of 48kWh/kg.

·      The Company's trial unit, installed by Lagan MEICA on behalf of
Northern Ireland Water in Belfast was independently tested and proven to be
producing hydrogen which exceeded 99.999mol% purity and oxygen at 99.7wt%.
This is an oxygen purity level consistent with medical grades.

·      A bottling trial of the same unit successfully compressed
hydrogen into a multi-cylinder pack ("MCP"), via a third-party compressor,
operated and tested as an integrated project.

·      CPH2 continues to build its sales pipeline in the UK and
internationally, with positive interest from credible customers in Germany,
Austria and Ireland, building on firm orders in Ireland and New Zealand.

The Company's next generation MFE220 unit has achieved a significant milestone
by passing the Factory Acceptance Test Level 1 and is now in transit to the
Company's test site to undertake Levels 2 & 3. The MFE220 unit also
successfully completed a bench test of the control system for the MFE process.
The simulation demonstrated full, efficient operational and safety systems
control.

The independent testing of the Company's trial unit in Belfast provides
notable, verifiable data points for technology validation with the production
of hydrogen which exceeded 99.999mol% purity and oxygen at 99.7wt%. These
results mean that oxygen is being produced at medical grades and the Company
is pleased that the test results match internal expectations for the
technology.

With the bottling trial of the same unit successfully delivering compressed
hydrogen into a MCP as part of an integrated project, the Company has achieved
a further technical milestone that validates its future technology pathway as
the trial unit and the MFE220 use the same patented technology. The
combination of bottling and high purity oxygen and hydrogen outputs provide
the opportunity for the Company to access new markets not previously served by
traditional hydrogen technology solutions. Access to these new markets should
accelerate sales pipeline build and deliver firm orders in robust and growing
markets that benefit from a known demand for decentralised hydrogen,
irrespective of government subsidy.

CPH2 will now focus its commercialisation phase into these identified,
decentralised, 'behind the meter' market sectors that the unique combination
of high purity hydrogen and oxygen output levels demonstrate a compelling
business case for. The market sectors include Semiconductor production, Data
Centre backup, Electricity grid support with wind and solar farm curtailment
solutions, Life Sciences, pharmaceutical and medical applications, more energy
efficient wastewater treatment, and biomass electricity plant enhancement.
This is in addition to the traditional return-to-base mobility applications
like buses, quarry vehicles, port, and airport handling machines.

With this key milestone completed and providing confidence in the MFE220
technology, the Board has instructed the Company's R&D and Engineering
teams to begin the FEED processes for a 5MW scale unit. Whilst the focus will
remain on delivering the successful on-site operation of the MFE220, the Board
considers it prudent to begin planning for future scale and growing end use
cases that could be achieved with the Company's technology. The initial
engineering assessment is that both the 5MW and existing 1MW unit can achieve
class leading efficiency of 48kWh/kg.

 

Jon Duffy, CEO of CPH2, commented:

"The second half of 2025 has seen CPH2 drive it's commercialisation phase with
technology wins enhancing our product market fit, culminating in the
successful completion of the Level 1 Factory Acceptance Test of the next
generation MFE220 1MW unit. This internal process was formally witnessed and
validated by our customer Lagan MEICA.

Building on this success CPH2 has commenced FEED on a 5MW unit, with initial
engineering assessment indicating that both the 1MW and 5MW units will be
capable of delivering class leading efficiency.

The high purity levels achieved for both hydrogen and oxygen opened-up new
important growth markets for CPH2, which is significant as the broader
hydrogen market continues to grow, as confirmed by the IEA report published in
September 2025, despite several large scale multi-billion dollar centralised
'green' projects having been delayed. CPH2 is a decentralised solution,
costing single digit millions, which operates behind the meter at a scale to
match the known requirements of mission-critical applications in high growth
markets.

The Company believes that its technology will be capable of delivering purity
levels of hydrogen and oxygen offtake, combined with production efficiency
across variable electricity loads that traditional electrolysers are not able
to match. The potential of these advances to open up new end use market
sectors is substantial.

The technology advances delivered throughout 2025 with the MFE solution are
helping to grow our sales pipeline and open new markets globally that do not
rely on government subsidies."

 

For more information, please contact:

 

 Clean Power Hydrogen plc
 Jon Duffy, Chief Executive Officer                            +44 (0)1302 328075
 James Hobson, Chief Financial Officer

 Cavendish Capital Markets Limited - NOMAD & Broker
 Neil McDonald                                                 +44 (0)131 220 9771
 Peter Lynch                                                   +44 (0)131 220 9772

 

To find out more, please visit: https://www.cph2.com (https://www.cph2.com/)

 

Overview of CPH2

CPH2 is the holding company of Clean Power Hydrogen Group Limited which has
almost a decade of dedicated research and product development experience. This
experience has resulted in the creation of simple, safe and sustainable
technology which is designed to deliver a modular solution to the hydrogen
production market in a cost-effective, scalable, reliable and long-lasting
manner. The Group's strategic objective is to deliver the lowest LCOH in the
market in relation to the production of green hydrogen. CPH2 is listed on the
AIM market and trades under the ticker LON:CPH2.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKOBNOBDDOBD



            Copyright 2019 Regulatory News Service, all rights reserved